These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Effect of aprotinin-induced kallikrein inhibition on the cardiovascular and renal action of captopril in diuretic-treated dogs.
    Author: Vemulapalli S, Chiu PJ.
    Journal: Arch Int Pharmacodyn Ther; 1983 Mar; 262(1):109-23. PubMed ID: 6191727.
    Abstract:
    By using aprotinin, a potent kallikrein inhibitor, the role of kinin formation in the cardiovascular and renal effects of captopril was assessed in pentobarbital-anesthetized dogs previously undergoing hydrochlorothiazide treatment (2.5 mg/kg, p.o., b.i.d.) for 5 days. A fall in mean arterial pressure (MBP) from 117 +/- 8 to 94 +/- 6 mmHg followed i.v. administration of captopril, 1 mg/kg. A concomitant rise in renal blood flow (RBF) from 168 +/- 18 to 205 +/- 20 ml/min occurred without changes in glomerular filtration rate (GFR) and with cardiac output tending to decrease. Urine flow (V) tended to rise while Na+ and K+ excretion were variable. With i.v. infusion of aprotinin (900 KIU/min) the hypotensive response to captopril was unaffected (from 103 +/- 5 to 75 +/- 8 mmHg) suggesting that captopril decreases BP independent of kinin accumulation. However, aprotinin completely abolished the renal vasodilator response to captopril (from 163 +/- 25 to 143 +/- 22 ml/min). In addition, there was a concomitant fall in GFR, V and electrolyte excretion. In comparison, the cardiovascular and renal effects of saralasin (3 micrograms/kg/min, i.v.) were not altered by aprotinin. It is, therefore, concluded that, in dogs with stimulated renin-angiotensin system, the plasma kinins do not contribute to the hypotensive action of captopril but play an important role in inducing renal vasodilatation and supporting kidney function.
    [Abstract] [Full Text] [Related] [New Search]